Johnson & Johnson Patient Organisation Transfers of Value Disclosure Methodology for 2024

1. Introduction

The information below describes the methodology that Janssen-Cilag Ltd, a Johnson & Johnson company (J&J) has applied to disclose the Transfers of Value (ToV) made to Patient Organisations in 2024. Transfers of Value to Patient Organisations are disclosed on the J&J public website (https://innovativemedicine.jnj.com/uk/how-we-work/transfer-of-value).

Note: On 1 May 2024, Janssen-Cilag Ltd updated its brand identity in the UK. The Company has updated its brand to unite both its pharmaceutical and MedTech segments under the Johnson & Johnson brand name.

2. Which payments will be included?

The following types of payments to identified Patient Organisations (as defined in Clause 1.15 of the 2024 ABPI Code of Practice) are disclosed:

- Provision of donations, grants and sponsorship to Patient Organisations as set out in Clause 23.2 and 27 of the 2024 ABPI Code of Practice
- Payments (made directly or indirectly via a third-party agent) for the provision of contracted services from Patient Organisations, including individuals representing Patient Organisations
- Payments of expenses associated with delivering contracted services

Non-financial benefit in kind provided to a Patient Organisations

3. What rules have J&J applied to be included for disclosure?

The following rules apply:

- Fees paid for contracted services, grants and sponsorships to Patient Organisations will be included in the calendar year in which J&J executed the payment or reimbursement in our financial systems
- ToV related to travel (e.g., flight and train tickets etc.), accommodation (e.g., hotel room cost), registration fees, will be included in the calendar year during which the activity/meeting took place. Out of pocket expenses paid directly to Patient Organisations are disclosed in the calendar year in which they were paid.
- ToV related to non-financial contributions will be included in the calendar year during which the activity took place
- In cases of payments processed via a third party acting on behalf of J&J, our payment date to the third party or the payment date provided by the third party is used as the determining factor to allocate the payment to the related calendar year.

Item Ref: CP-526496 Date of preparation: June 2025

Johnson&Johnson

4. What information is disclosed for each ToV?

The information displayed on the website includes:

- Name of Patient Organisation
- Organisation address
- · Country of organisation
- Date of contract*
- · Description of activity
- Amount of non-financial or financial support or fee-for-service paid.

5. How are expenses related to contracted services disclosed?

If a Patient Organisation or individual representing a Patient Organisation performed a contracted service the related cost of travel, accommodation arrangements and any reimbursement of out-of-pocket expenses, as per the contract terms, are reported in the description of the activity.

6. What is reported in cases of cancellation?

- Travel costs are not reported as ToV if the Patient Organisation is unable to utilise the booking.
- Cancellation fees for travel are not reported.

7. How does J&J report non-monetary value for ToV for benefits in kind made to Patient Organisations?

J&J discloses benefits in kind as non-financial ToV which is calculated via an assessment of the fair market value of the benefit to the Patient Organisation and is included in the contract between J&J and the Patient Organisation.

8. How does J&J report ToV related to multi-year contracts?

Where contracts span multiple years, each individual annual ToV is captured and disclosed in the corresponding reporting period.

9. Is VAT included?

Direct payments are disclosed exclusive of VAT, if applicable. All ToV for travel and accommodation (e.g., flight ticket, hotel room, etc.) are reported inclusive of VAT, where applicable.

Item Ref: CP-526496 Date of preparation: June 2025

^{*} Date of contract = Activity start date

Johnson&Johnson

The disclosure reported ToV amounts should not be used for VAT/Tax reporting purposes. If fiscal reports are required, the company provides them directly to the Patient Organisation.

10. Do all J&J affiliate companies have a duty to disclose ToVs made to Patient Organisations based in the UK?

Yes, all European and global J&J affiliates have a duty to disclose all ToVs made to Patient Organisations based in the UK.

11. What has J&J excluded from the Disclosure report?

Third-party recipients of donations from independent charitable organisations which have themselves received donations from J&J and are not otherwise subject to disclosure. In the case of the Johnson & Johnson Foundation Scotland (an independent charity), any third-party recipients of donations from the Foundation will be published in its' audited annual directors' reports: https://www.jnjfoundation.com/.

12. How are different currencies handled?

All values reported are in GBP. For ToV that was originally paid in a different currency, a conversion to local currency is made. Exchange rate details can be provided on a case-by-case basis.

Disclaimer

J&J relies on a combination of automated systems, standardised processes, and manual data entry from internal and external resources to record and report relevant ToV data. The information reported in this submission is done in good faith and best efforts to comply with the disclosure requirements of the ABPI Code of Practice. Although J&J strive for efficient and fast processing, it might occur that payment information becomes available only after the date of publishing. Should we, despite our best efforts to ensure accurate reporting, fail to include complete and correct information in our submission, we will appropriately investigate and address in case of erroneous information. J&J expect this to be exceptional and will monitor actual occurrences. In case of significant changes to the initial publication J&J will publish an amendment within a reasonable timeframe.

Should a Patient Organisation consider that the report is incomplete or incorrect, please contact us via disclosure@Janssen.co.uk and we will make appropriate changes as soon as possible.

A link to J&J ToV data is provided to the ABPI for the purpose of meeting ABPI reporting requirements.

Item Ref: CP-526496 Date of preparation: June 2025